Modern Medicine Cases

New pathways to cancer therapyA novel oral formulation of itraconazole (SUBA-Itraconazole, HedgePath Pharmaceuticals) is providing dramatic benefit for patients with basal cell carcinoma nevus syndrome (BCCNS, also known as Gorlin syndrome) and with a favorable safety profile, according to a recent interim analysis of data collected in a phase IIb study.
A wake-up call for physiciansEveryone knows the name of Warren Buffett, the famous octogenarian-billionaire businessman and investor. His folksy persona and investment insights/elevated returns have earned him the appellation of “The Oracle of Omaha.” His estimated net worth of more than $74 billion makes him one of the wealthiest people on the planet.
Quantifying ectasia risk after LASIKA preliminary analysis of a dataset containing more than 300,000 eyes treated with LASIK between 6 to 10 years ago is beginning to quantify some of the risks for ectasia.
POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.
Managing conjunctival pigmented lesionsKnowing how to recognize and manage the various forms of conjunctival pigmented lesions can literally mean the difference between life and death in some cases.
Consider different iris lesion forms before final clinical diagnosis
Consider different iris lesion forms before final clinical diagnosisUse these pearls to better diagnose and treat iris lesions.
Selective techniques revolutionize treatment for retinoblastomaAdvancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseasesThe gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
Aspiring for zero tolerance of residual astigmatism
Aspiring for zero tolerance of residual astigmatismWhen considering premium surgeries and high expectations from patients along with an unrelenting quest for vision exceeding 20/20, the tolerance of residual astigmatism must be zero. Like bespoke tailors, ophthalmologists need to be bespoke surgeons who tailor vision in each eye to the highest level possible. We cannot claim to design the best suit using the best technology and tailoring materials, and yet, in our minds, find it “acceptable” to have the suit length within a half-inch to three-quarters of an inch too short or wide.